Pentoxifylline Decreases Dialysis Risk in Patients with Advanced Chronic Kidney Disease

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 4, 2015, Pages 442-449

  Wu, P C ^a,b   Wu, C J ^a,c,d   Lin, C J ^a,c,e   Pan, C F ^a   Chen, C Y ^a   Huang, T M ^f   Wu, C H ^g   Lin, S L ^f   Chen, Y M ^f   Chen, L ^h   Wu, V C ^f  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c MACKAY MEDICAL COLLEGE   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g TZU CHI UNIVERSITY   (Taiwan)

^h NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PENTOXIFYLLINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; URINARY TRACT AGENT;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; RISK REDUCTION; AGED; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CREATININE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PENTOXIFYLLINE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UROLOGICAL AGENTS;

EID: 84952759707     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.173     Document Type: Article

References (47)

1. Hallan, S.I., Ritz, E., Lydersen, S., Romundstad, S., Kvenild, K. & Orth, S.R. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J. Am. Soc. Nephrol. 20, 1069-1077 (2009).
2. Hemmelgarn, B.R. et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303, 423-429 (2010).
3. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1-150 (2013).
4. Ruggenenti, P., Cravedi, P. & Remuzzi, G. Mechanisms and treatment of CKD. J. Am. Soc. Nephrol. 23, 1917-1928 (2012).
5. Brenner, B.M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
6. Lin, S.L., Chen, Y.M., Chiang, W.C., Tsai, T.J. & Chen, W.Y. Pentoxifylline: a potential therapy for chronic kidney disease. Nephrology (Carlton) 9, 198-204 (2004).
7. Frampton, J.E. & Brogden, R.N. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 7, 480-503 (1995).
8. Badri, S., Dashti-Khavidaki, S., Lessan-Pezeshki, M. & Abdollahi, M. A review of the potential benefits of pentoxifylline in diabetic and nondiabetic proteinuria. J. Pharm. Pharm. Sci. 14, 128-137 (2011).
9. Harmankaya, O., Seber, S. & Yilmaz, M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren. Fail. 25, 465-470 (2003).
10. Navarro, J.F., Mora, C., Muros, M. & García, J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J. Am. Soc. Nephrol. 16, 2119-2126 (2005).
11. Cooper, A., Mikhail, A., Lethbridge, M.W., Kemeny, D.M. & Macdougall, I.C. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J. Am. Soc. Nephrol. 15, 1877-1882 (2004).
12. Navarro-González, J.F. et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J. Am. Soc. Nephrol. 26, 220-229 (2015).
13. Solerte, S.B. et al. Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study. Acta Diabetol. Lat. 23, 171-177 (1986).
14. Rodriguez-Morán, M. et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin. Nephrol. 66, 3-10 (2006).
15. Navarro, J.F. et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 33, 458-463 (1999).
16. Diskin, C.J., Stokes, T.J., Dansby, L.M., Radcliff, L. & Carter, T.B. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker? J. Nephrol. 20, 410-416 (2007).
17. Chen, Y.M., Lin, S.L., Chiang, W.C., Wu, K.D. & Tsai, T.J. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 69, 1410-1415 (2006).
18. Galindo-Rodríguez, G. et al. Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. J. Rheumatol. 30, 2382-2384 (2003).
19. Lin, S.L., Chen, Y.M., Chiang, W.C., Wu, K.D. & Tsai, T.J. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am. J. Kidney Dis. 52, 464-474 (2008).
20. Perkins, R.M., Aboudara, M.C., Uy, A.L., Olson, S.W., Cushner, H.M. & Yuan, C.M. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am. J. Kidney Dis. 53, 606-616 (2009).
21. Goicoechea, M. et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J. Nephrol. 25, 969-975 (2012).
22. Lin, S.L., Chiang, W.C., Chen, Y.M., Lai, C.F., Tsai, T.J. & Hsieh, B.S. The renoprotective potential of pentoxifylline in chronic kidney disease. J. Chin. Med. Assoc. 68, 99-105 (2005).
23. Ducloux, D., Bresson-Vautrin, C. & Chalopin, J. Use of pentoxifylline in membranous nephropathy. Lancet 357, 1672-1673 (2001).
24. Navarro, J.F., Mora, C., Muros, M., Maca, M. & Garca, J. Effects of pentoxifylline administration on urinary N-acetyl-betaglucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. Am. J. Kidney Dis. 42, 264-270 (2003).
25. Park, S.H. et al. Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy. Am. J. Nephrol. 37, 491-500 (2013).
26. Waldum, B. & Os, I. The cardiorenal syndrome: what the cardiologist needs to know. Cardiology 126, 175-186 (2013).
27. Werner, C. et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin. Res. Cardiol. 97, 418-431 (2008).
28. Lewis, E.J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
29. Chen, P.M. et al. Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease. J. Formos. Med. Assoc. 113, 219-226 (2014).
30. Hwang, S.J., Yang, W.C., Lin, M.Y., Mau, L.W., Chen, H.C. & Taiwan Society of Nephrology. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrol. Dial. Transplant. 25, 2616-2624 (2010).
31. Johnson, D.W. et al. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the handling erythropoietin resistance with oxpentifylline (HERO) trial. Am. J. Kidney Dis. 65, 49-57 (2015).
32. Keane, W.F. et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 63, 1499-1507 (2003).
33. Palmer, S.C. et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst. Rev. 12, CD010590 (2014).
34. Gordon, J. & Kopp, J.B. Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. Adv. Chronic Kidney Dis. 18, 300-311 (2011).
35. Wu, V.C. et al. Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan. J. Clin. Epidemiol. 67, 1139-1149 (2014).
36. Wang, W.J. et al. The impact of acute kidney injury with temporary dialysis on the risk of fracture. J. Bone Miner. Res. 29, 676-684 (2014).
37. Wu, V.C. et al. Long-term risk of coronary events after AKI. J. Am. Soc. Nephrol. 25, 595-605 (2014).
38. Cheng, C.L., Kao, Y.H., Lin, S.J., Lee, C.H. & Lai, M.L. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol. Drug Saf. 20, 236-242 (2011).
39. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373-383 (1987).
40. World Health Organization. The ATC and DDD system. (2011). Accessed 20 October 2011.
41. Hsu, T.W. et al. Renoprotective effect of renin-angiotensinaldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern. Med. 174, 347-354 (2014).
42. Lai, T.S. et al. Risk of developing severe sepsis after acute kidney injury: a population-based cohort study. Crit. Care 17, R231 (2013).
43. Shariff, S.Z., Cuerden, M.S., Jain, A.K. & Garg, A.X. The secret of immortal time bias in epidemiologic studies. J. Am. Soc. Nephrol. 19, 841-843 (2008).
44. Shintani, A.K., Girard, T.D., Eden, S.K., Arbogast, P.G., Moons, K.G. & Ely, E.W. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit. Care Med. 37, 2939-2945 (2009).
45. Wu, V.C. et al. Acute-on-chronic kidney injury at hospital discharge is associated with long-term dialysis and mortality. Kidney Int. 80, 1222-1230 (2011).
46. Woo, M.J., Reiter, J.P. & Karr, A.F. Estimation of propensity scores using generalized additive models. Stat. Med. 27, 3805-3816 (2008).
47. Lin, J.H., Wang, W.J., Wu, V.C., Wu, K.D. & TAIPAI Study Group. Eligibility for statin therapy according to new cholesterol guidelines on primary aldosteronism. J. Clin. Endocrinol. Metab. (2015); e-pub ahead of print.